MNKD-201

N/A

Report date: 2024/08/06 16:23:23

Base Information

Drug NameMNKD-201
Drug Alias Namenintedanib DPI (Mannkind Corporation)MNKD-201MKND-201
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionColony stimulating factor 1 receptor inhibitorsFibroblast growth factor receptor 2 antagonistsPlatelet-derived growth factor receptor beta inhibitors +[10] 
TargetsColony stimulating factor 1 receptorFibroblast growth factor receptor 2Platelet-derived growth factor receptor beta +[10] 
Therapy Area/IndicationsIdiopathic Pulmonary Fibrosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesMannKind Corp
China Registration ClassN/A

Develop Information

Active CompaniesMannKind Corp
Inactive CompaniesN/A
Active IndicationsIdiopathic Pulmonary Fibrosis
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A